Gained alignment with global health authorities for pivotal Phase 3 SEACRAFT-2 trial design for naporafenib plus trametinib in NRAS mutant…
AGOURA HILLS, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”),…
SAN DIEGO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a…
PRESS RELEASE - 22 November 2023, 10:00 CET BIOCARTIS HOLDINGS INC. RECAPITALIZATION COMPLETED AND PRODUCT PORTFOLIO EXPANSION The recapitalization of…
MIAMI--(BUSINESS WIRE)--DermaSensor Inc. – Skin cancer is a global health concern, with increasing incidence rates worldwide. Artificial Intelligence (AI) is…
JERUSALEM, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau") (NASDAQ: DRTS, DRTSW), the developer of the…
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business UpdateEnrollment completed for…
Cash runway extended through multiple data readouts and into Q1 of calendar 2025 MDNA11 is generally well tolerated and continues…
Advances Non-Viral DNA-Mediated Cancer Immunotherapy and Next-Generation Vaccine Programs, with More Potent and Durable Immunity, with Multiple Near-Term Milestones Conference…
ACTengine® IMA203 GEN1 TCR-T targeting PRAME showed 50% (6/12) confirmed ORR in melanoma patients with median duration of response (mDOR)…